FDA shuffles top drug, biologics leaders in latest shakeup
The U.S. Food and Drug Administration is shuffling its top drug and biologics regulators, days after the departure of former commissioner Marty Makary.
AI Summary
The FDA has reassigned its top drug and biologics regulators, with Tracy Beth Høeg and Katherine Szarama stepping down from their acting director roles overseeing prescription drugs and vaccines. Karim Mikhail will replace Høeg at the Center for Drug Evaluation and Research, while Michael Davis will replace Szarama at the Center for Biologics Evaluation and Research. This leadership shuffle follows former FDA Commissioner Marty Makary's recent resignation and reflects ongoing instability at the agency, which has seen five different leaders in one division since January.